Article info
Interstitial lung disease
Effects of infliximab on lung and circulating natural killer cells, CD56+ T cells and B cells in sarcoidosis
- Correspondence to Dr Susanna Kullberg; susanna.kullberg{at}ki.se
Citation
Effects of infliximab on lung and circulating natural killer cells, CD56+ T cells and B cells in sarcoidosis
Publication history
- Received March 24, 2021
- Accepted May 15, 2021
- First published July 7, 2021.
Online issue publication
July 07, 2021
Supplementary Data
This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY. Published by BMJ. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: https://creativecommons.org/licenses/by/4.0/.